[go: up one dir, main page]

TNSN99210A1 - Identification de genotypes du virus sen - Google Patents

Identification de genotypes du virus sen

Info

Publication number
TNSN99210A1
TNSN99210A1 TNTNSN99210A TNSN99210A TNSN99210A1 TN SN99210 A1 TNSN99210 A1 TN SN99210A1 TN TNSN99210 A TNTNSN99210 A TN TNSN99210A TN SN99210 A TNSN99210 A TN SN99210A TN SN99210 A1 TNSN99210 A1 TN SN99210A1
Authority
TN
Tunisia
Prior art keywords
acid molecule
nucleic acid
virus
genome
relates
Prior art date
Application number
TNTNSN99210A
Other languages
English (en)
Inventor
Daniele Primi
Gianfranco Fiordalisi
Giovanni Lorenzo Mantero
Sonia Mattioli
Alessandra Sottini
Fabrizio Bonelli
Laura Vaglini
Paolo Olivero
Corso Andrea Dal
Marco Bonelli
Original Assignee
Diasorin S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI982437 external-priority patent/IT1303732B1/it
Priority claimed from ITMI990923 external-priority patent/IT1312552B1/it
Application filed by Diasorin S R L filed Critical Diasorin S R L
Publication of TNSN99210A1 publication Critical patent/TNSN99210A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

LA PRESENTE INVENTION SE RAPPORTE A UNE MOLECULE D'ACIDE NUCLEIQUE REPRESENTANT LE GENOME D'UN AGENT VIRAL/VIRUS, LADITE MOLECULE D'ACIDE NUCLEIQUE AYANT, AU MOINS, UNE DES CARACTERISTIQUES SUIVANTES : (a) ELLE CONTIENT, AU MOINS, UN CADRE DE LECTURE OUVERT (ORF) QUI ENCODE UN POLYPEPTIDE AYANT UNE SEQUENCE D'ACIDE AMINE DIVULGUEE DANS CE DOCUMENT, (b) ELLE COMPREND UNE SEQUENCE ADN COMME DECRIT DANS CE DOCUMENT, (c) ELLE S'HYBRIDE, DE PREFERENCE, DANS DES CONDITIONS ASTRINGENTES EN UN BRIN COMPLEMENTAIRE DE LA MOLECULE D'ACIDE NUCLEAIRE DECRITE ICI, MAIS PAS EN UN BRIN COMPLEMENTAIRE DU GENOME DU VIRUS TT ; (d) ELLE EST DEGENEREE PAR RAPPORT A LA MOLECULE D'ACIDE NUCLEIQUE HYBRIDANTE, (e) ELLE EST IDENTIQUE A, AU MOINS, 60% A LA MOLECULE D'ACIDE NUCLEIQUE REPRESENTANT LE GENOME DE L'AGENT VIRAL/VIRUS DE L'INVENTION ; ET (f) DES PARTIES DE CETTE MOLECULE PEUVENT ETRE AMPLIFIEES DANS DES CONDITIONS APPROPRIEES PAR PCR UTILISANT DES CATALYSEURS COMME DEFINI ICI. L'INVENTION SE RAPPORTE A DES VECTEURS COMPRENANT LADITE MOLECULE D'ACIDE NUCLEIQUE, DES METHODES DE PRODUCTION DE (POLY)PEPTIDE(S) ENCODES PAR LADITE MOLECULE D'ACIDE NUCLEIQUE ET ANTICORPS AUX DITS POLY(PEPTIDES)s ET/OU LESDITS AGENTS VIRUS/VIRAUX. EN PLUS, L'INVENTION SE RAPPORTE A DES COMPOSITIONS, DE PREFERENCE, DES COMPOSITIONS PHARMACEUTIQUES, DES VACCINS, DES DIAGNOSTICS ET KITS DE DIAGNOSTIC COMPRENANT OU UTILISANT DES COMPOSES DE L'INVENTION.
TNTNSN99210A 1998-11-10 1999-11-08 Identification de genotypes du virus sen TNSN99210A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI982437 IT1303732B1 (it) 1998-11-10 1998-11-10 Molecole di acido nucleico che rappresentano un virus trasmissibileper via parenterale.
ITMI990923 IT1312552B1 (it) 1999-04-30 1999-04-30 Molecole di acido nucleico che rappresentano un virus trasmissibileper via parenterale
EP99830298 1999-05-14
EP99113932 1999-07-16

Publications (1)

Publication Number Publication Date
TNSN99210A1 true TNSN99210A1 (fr) 2005-11-10

Family

ID=27443821

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99210A TNSN99210A1 (fr) 1998-11-10 1999-11-08 Identification de genotypes du virus sen

Country Status (8)

Country Link
EP (1) EP1137779A2 (fr)
JP (1) JP2002529092A (fr)
AR (1) AR021143A1 (fr)
AU (1) AU1381600A (fr)
NO (1) NO20012276L (fr)
PE (1) PE20001331A1 (fr)
TN (1) TNSN99210A1 (fr)
WO (1) WO2000028039A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042299A2 (fr) * 1999-12-10 2001-06-14 Roche Diagnostics Gmbh Virus sentinelle i du virus de l'hepatite (svi)
DE10007234A1 (de) * 2000-02-17 2001-10-18 Sension Biolog Detektions Und Peptid und dafür kodierende Nukleinsäure zur Bestimmung, Diagnostik und Therapie von Erkrankungen des Nervensystems
DE10144346A1 (de) * 2001-09-10 2003-04-03 Deutsches Krebsforsch TT-Virus-Sequenzen in menschlichen Tumorgeweben, Mittel zu deren Nachweis sowie Tumortherapie
EP2585477B1 (fr) * 2010-06-23 2018-05-30 Deutsches Krebsforschungszentrum Molécules virales tt réarrangées pouvant être utilisées pour diagnostiquer, prévenir et traiter le cancer et l'auto-immunité
US20110318363A1 (en) 2010-06-23 2011-12-29 Deutsches Krebsforschungszentrum Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
DK2399928T3 (da) * 2010-06-23 2018-01-29 Deutsches Krebsforsch Specifikke TT-virus-sekvenser og kimæriske TT-virusværtscelle-DNA-molekyler til anvendelse ved diagnosticering, forebyggelse og behandling af cancer og auto-immunitet
US9676828B2 (en) 2010-06-23 2017-06-13 Deutsches Krebsforschungszentrum Rearranged TT virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2298103A1 (fr) * 1997-07-25 1999-02-04 Tamura, Ryoji Gene du virus de l'hepatite non-b, non-c, non-g, polynucleotide, polypeptide, particule de virus, procede d'isolation du particule de virus et procede de detection de ce virus
AU4259299A (en) * 1998-05-13 1999-11-29 Innogenetics N.V. New sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections

Also Published As

Publication number Publication date
PE20001331A1 (es) 2000-12-19
NO20012276D0 (no) 2001-05-09
EP1137779A2 (fr) 2001-10-04
WO2000028039A3 (fr) 2000-10-05
WO2000028039A2 (fr) 2000-05-18
AU1381600A (en) 2000-05-29
JP2002529092A (ja) 2002-09-10
AR021143A1 (es) 2002-06-12
NO20012276L (no) 2001-07-09

Similar Documents

Publication Publication Date Title
US7507529B2 (en) Oligonucleotides originating from sequences coding for the surface component of PTLV envelope proteins and their uses
JP2005538696A5 (fr)
EP0984067A3 (fr) Séquences des génotypes du virus de l'hépatite C, et son utilisation comme agents thérapeutiques et diagnostiques
WO2005056584A3 (fr) Nouvelle souche de coronavirus associe au sras et ses applications.
EP1832599A3 (fr) Proteines de fusion d'albumine
MA46230A (fr) Mutations de protéine d'enveloppe du vih stabilisant la forme trimère
TNSN99210A1 (fr) Identification de genotypes du virus sen
WO1992019743A3 (fr) Sequences genomiques du virus de l'hepatite c utilisees en diagnostic et en therapeutique
EP3083946B1 (fr) Déplétion de cellules dendritiques plasmacytoïdes
DE69534600D1 (de) Nukleotid- und aminosäuresequenzen der gene des hüllproteins 1 und des kernproteins von hepatitis c virus
MA27699A1 (fr) Vaccin contre vhc
Young et al. Different rat-derived transforming retroviruses code for an immunologically related intracellular phosphoprotein.
EP1613345A4 (fr) Compositions contenant un virus syncytial respiratoire de la souche 9320 du sous-groupe b, et procedes associes
WO2003022202A3 (fr) Compositions et methodes pour le traitement du cancer
WO1996021020A3 (fr) Sequences virales de la maladie de borna et procedes diagnostiques et therapeutiques destines aux affections du systeme nerveux
WO2004014936A3 (fr) Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications.
Motoyoshi et al. Resolution of the Polypeptide Chain Elongation Factor-1βγ into Subunits and Some Properties of the Subunits
US20240218347A1 (en) Polymer of Protein-Conjugated Polysaccharide, Preparation Method Therefor, Enzyme-Stabilizing Composition Comprising Same, and Method for Detecting Target Nucleic Acid Molecule by Using Same
WO2004031222A3 (fr) Vaccin
EP1383796B1 (fr) Souche neurovirulente du virus west-nile et ses applications
Tognon et al. Investigation of the simian polyomavirus SV40 as a potential causative agent of human neurological disorders in AIDS patients
CA2423045A1 (fr) Vecteurs adenoviraux d'apport de genes dans des cellules de muscles squelettiques ou myoblastes
US20250270525A1 (en) Methods and compositions relating to a group ii intron reverse transcriptase
WO2003051174A3 (fr) Polymorphismes de nucleotide unique (snp) et ses mutations dans l'alpha-2-macroglobuline
EP4317176A1 (fr) Composition de vaccin à base de réovirus atténué et son utilisation